Health Condition 1: L102- Pemphigus foliaceous Health Condition 2: L100- Pemphigus vulgaris
Conditions
Interventions
None listed
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: Patients with confirmed pemphigus vulgaris or foliaceus treated with RTX- RA protocol.
Exclusion criteria
Exclusion criteria: 1. Patients who have received RTX cycles in the preceding one year. 2. Patients with other concomitant autoimmune diseases. 3. Pregnant and lactating patients. 4. Patients who cannot come for follow up visits for at least 18 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Comparison of the changing trends of anti-dsg1, anti-dsg3, and anti-AchR (M3) antibody values between patients who relapse and who do not relapse. 2. Comparison of changing trends of CD 19+ and CD19+27+ B cells between relapsing and non-relapsing patients. 3. Comparison of baseline clinical parameters between relapsing and non-relapsing during the first two years after the initial cycle of rituximab. Timepoint: Baseline, 3, 6, 9, 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Comparison of baseline immunological and clinical parameters between patients who experience disease flare and those who do not at the end of first month. Timepoint: Baseline, 4 weeks | — |
Countries
India
Contacts
Public ContactDr Sindhuja
All India Institute of Medical Sciences
Outcome results
None listed